MIAMI, Fla., December 17, 2025 — Veru Inc., a late-stage biopharmaceutical company, reported its fiscal year 2025 financial results alongside significant clinical program progress centered on enobosarm, its selective androgen receptor modulator being developed for high-quality weight reduction in combination with GLP-1 receptor agonists. The update highlights positive Phase 2b QUALITY study outcomes, newly received FDA regulatory clarity, and plans to initiate the Phase 2b PLATEAU clinical study in early 2026, positioning Veru at the forefront of next-generation obesity therapeutics.
Science Significance
Scientifically, Veru’s data reinforce a growing paradigm shift in obesity treatment: weight loss quality matters as much as magnitude. Results from the Phase 2b QUALITY study demonstrated that enobosarm preserved 100% of lean mass while increasing fat loss when combined with semaglutide, compared with GLP-1 therapy alone. Importantly, physical function—measured by the stair climb test—declined significantly in patients receiving semaglutide alone, whereas enobosarm substantially reduced this decline. These findings support the hypothesis that muscle preservation can enhance metabolic efficiency, improve function, and potentially overcome weight-loss plateaus, addressing a major limitation of current GLP-1 monotherapy.
Regulatory Significance
From a regulatory standpoint, Veru reported clear and actionable FDA feedback following a September 2025 meeting. The agency confirmed that incremental weight loss is an acceptable approvable primary endpoint for enobosarm in combination with a GLP-1 RA, with clinically meaningful physical function benefits serving as key secondary endpoints. FDA also confirmed enobosarm 3 mg as an acceptable dose for continued development. This clarity de-risks the program and informs the design of the PLATEAU Phase 2b study, aligning endpoints with regulatory expectations and strengthening the pathway toward late-stage development.
Business Significance
Advertisement
Financially, Veru demonstrated progress in aligning resources with pipeline advancement. R&D investment increased, reflecting focus on clinical execution, while operating losses narrowed year over year. Post fiscal year-end, the company completed a public offering generating approximately $23.4 million in net proceeds, extending runway to support the upcoming PLATEAU trial. The combination of capital access, regulatory clarity, and differentiated clinical data enhances Veru’s strategic positioning for partnerships in a highly competitive obesity market increasingly dominated by GLP-1-based regimens.
Patients’ Significance
For patients—particularly older adults with obesity—the implications are substantial. GLP-1 therapies deliver meaningful weight loss but are often accompanied by muscle loss, functional decline, and weight-loss plateaus. Veru’s approach aims to deliver fat-selective weight reduction while preserving muscle and physical function, potentially reducing fall risk, frailty, and long-term disability. If confirmed in longer studies, this strategy could offer patients a more sustainable and functional weight-loss journey, improving quality of life beyond the number on the scale.
Policy Significance
At the policy level, the program aligns with evolving definitions of obesity as a disease of excess body fat rather than simple body weight. Regulators and health systems are increasingly focused on outcomes that matter to patients, including function and long-term health. Veru’s engagement with FDA on novel endpoints reflects policy momentum toward holistic efficacy measures, supporting reimbursement models that reward durable, quality-focused outcomes in chronic disease management.
Veru’s fiscal 2025 update underscores a convergence of science, regulation, and strategy around enobosarm as a potential next-generation adjunct to GLP-1 therapy. With compelling Phase 2b data, clear FDA guidance, secured financing, and a defined path into the PLATEAU Phase 2b study, the company is advancing a differentiated approach to obesity treatment focused on fat loss, muscle preservation, and functional health. As obesity drug development evolves, Veru’s program highlights how quality of weight reduction may shape the future of metabolic medicine.
Source: Veru Inc. press release
